INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 263 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,637,042 | -22.3% | 399,653 | +0.2% | 0.00% | 0.0% |
| Q2 2023 | $16,273,076 | +18.7% | 399,046 | +8.5% | 0.00% | 0.0% |
| Q1 2023 | $13,713,032 | +3.8% | 367,938 | -2.9% | 0.00% | 0.0% |
| Q4 2022 | $13,214,572 | -30.9% | 378,750 | +10.8% | 0.00% | -40.0% |
| Q3 2022 | $19,135,000 | +23.3% | 341,947 | +14.1% | 0.01% | +25.0% |
| Q2 2022 | $15,514,000 | -27.5% | 299,739 | +1.8% | 0.00% | 0.0% |
| Q1 2022 | $21,407,000 | -38.8% | 294,571 | -0.4% | 0.00% | -33.3% |
| Q4 2021 | $34,967,000 | -12.8% | 295,719 | -1.1% | 0.01% | -25.0% |
| Q3 2021 | $40,103,000 | -5.9% | 298,945 | +13.6% | 0.01% | 0.0% |
| Q2 2021 | $42,599,000 | +161.6% | 263,115 | +29.7% | 0.01% | +166.7% |
| Q1 2021 | $16,287,000 | +46.3% | 202,928 | -0.9% | 0.00% | +50.0% |
| Q4 2020 | $11,135,000 | +198.0% | 204,676 | +8.9% | 0.00% | +100.0% |
| Q3 2020 | $3,737,000 | -4.7% | 187,969 | +0.7% | 0.00% | 0.0% |
| Q2 2020 | $3,923,000 | +85.5% | 186,609 | +7.9% | 0.00% | 0.0% |
| Q1 2020 | $2,115,000 | -35.6% | 172,966 | -22.8% | 0.00% | 0.0% |
| Q4 2019 | $3,286,000 | +14.7% | 223,967 | +4.4% | 0.00% | 0.0% |
| Q3 2019 | $2,865,000 | +18.1% | 214,602 | +44.9% | 0.00% | 0.0% |
| Q2 2019 | $2,425,000 | +12.9% | 148,132 | +17.8% | 0.00% | 0.0% |
| Q1 2019 | $2,148,000 | +28.1% | 125,746 | +2.4% | 0.00% | 0.0% |
| Q4 2018 | $1,677,000 | -55.3% | 122,851 | -6.3% | 0.00% | 0.0% |
| Q3 2018 | $3,751,000 | +11.0% | 131,051 | +6.1% | 0.00% | 0.0% |
| Q2 2018 | $3,379,000 | +101.6% | 123,494 | +55.4% | 0.00% | – |
| Q1 2018 | $1,676,000 | +18.9% | 79,479 | +8.4% | 0.00% | – |
| Q4 2017 | $1,409,000 | -23.1% | 73,324 | -0.6% | 0.00% | -100.0% |
| Q3 2017 | $1,832,000 | +109.1% | 73,739 | +34.6% | 0.00% | – |
| Q2 2017 | $876,000 | +96.4% | 54,802 | +73.0% | 0.00% | – |
| Q1 2017 | $446,000 | +13.2% | 31,676 | +5.6% | 0.00% | – |
| Q4 2016 | $394,000 | +12.3% | 29,994 | +45.7% | 0.00% | – |
| Q3 2016 | $351,000 | -24.0% | 20,591 | -4.8% | 0.00% | – |
| Q2 2016 | $462,000 | – | 21,626 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |